The US Food and Drug Administration approved on 15 November Novartis’s Adakveo, a new treatment to reduce vaso-occlusive crises (VOCs), or pain crises in sickle cell disease.
FDA Approval For Novartis’s Sickle Cell Treatment Adakveo
Gains Nod Ahead Of Global Blood Therapeutics’ Contender
One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.
More from New Products
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.